The Office of Prescription Drug Promotion (OPDP)
(formerly Division of Drug Marketing, Advertising and Communications - DDMAC)
10903 New Hampshire Ave., Building 51, Room 3203
Silver Spring, MD 20993-0002
Phone and Fax Numbers:
Fax: 301-847-8444 or 301-847-8445
"To protect the public health by assuring prescription drug information is truthful, balanced and accurately communicated. This is accomplished through a comprehensive surveillance, enforcement and education program, and by fostering better communication of labeling and promotional information to both healthcare professionals and consumers."
OPDP has transitioned to a new tracking system. There are new requirements when submitting requests for advisory. For more information, please refer to the following:
- OPDP Submission of Proposed DTC TV Ads for Advisory Review
- Requests for Advisory Comment on Promotional Materials Other than Proposed DTC TV Ads
OPDP Issues Revised Draft Guidance on Brief Summary and Adequate Directions for Use Requirements
On February 6, 2015, OPDP issued a revised draft guidance for public comment entitled Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs. The revised draft guidance responds to stakeholder requests for specific guidance on disclosure of risk information to consumers and incorporates recent social science research results. This revised draft guidance pertains to what is commonly known as the “brief summary requirement” for consumer-directed print advertisements and to the requirement that certain information be included with consumer-directed print promotional labeling pieces for human prescription drugs and biologics. The guidance revises the January 2004 draft guidance entitled Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements.
OPDP releases internet and social media guidances
Technology is continually changing, but FDA’s commitment to public health does not. In today’s world, a tremendous amount of information exchange occurs on the web and through social media. On June 17, 2014, FDA’s Office of Prescription Drug Promotion released two highly-anticipated guidances related to the November 2009 Part 15 public hearing discussion topics that provide FDA’s current views and recommendations for medical product companies who wish to use the Internet/social media. FDA received public comments on these guidances during two open comment periods. FDA is currently reviewing the comments and plans to update the documents accordingly. To see the guidances and learn more, please visit our social media guidances webpage.
New Form FDA-2253
Risk Communication Advisory Committee; Notice of Meeting
Information About What OPDP Reviewers Do
OPDP reviewers have responsibility for reviewing prescription drug advertising and promotional labeling to ensure that the information contained in these promotional materials is not false or misleading. They engage in a variety of tasks to perform this responsibility, including: providing written comments to pharmaceutical sponsors on proposed promotional materials to ensure clear and unambiguous communication of the laws and regulations relating to prescription drug promotion; reviewing complaints about alleged promotional violations; initiating enforcement actions on promotional materials that are false or misleading; comparing the product labeling and promotional materials of various closely related products to ensure that the regulatory requirements are consistently and equitably applied; traveling to major medical meetings and pharmaceutical conventions to monitor promotional exhibits and activities; and acting as a liaison between OPDP and other divisions within the FDA on promotional issues. Interested in a position at OPDP?
Important Information About Submissions
OPDP reminds all companies who are engaging in DTC advertising of prescription drugs that the requirements of section 906 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) went into effect on March 25, 2008. Section 906 of FDAAA mandates that published direct-to-consumer advertisements for prescription drugs include the following statement printed in conspicuous text: "You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088."
Proposed DTC TV Advertisements Voluntarily Submitted for OPDP Advisory Review
Please visit OPDP’s submission page for information on the components of a complete and reviewable DTC TV submission package, and for information on other submissions.
Truthful Prescription Drug Advertising and Promotion (Bad Ad Program)
The Prescriber's Role - Recognize and Report
FDA's educational outreach program is designed to educate healthcare providers about the role they can play in helping the agency make sure that prescription drug advertising and promotion is truthful and not misleading.
The "Bad Ad" Program is administered by the agency's Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research. It will help healthcare providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency.
Information about the status of the DTC user fee program enacted under the Food and Drug Administration Amendments Act of 2007 (FDAAA) is posted at the
OPDP Submission Information
Information on the components of a complete and reviewable DTC TV submission package, and for information on other submissions.